About: Health and Pharma
Parliament wants harmonised criteria for drug pricing and reimbursement
The European Parliament will seek an increased EU role in regulating the pharmaceutical market and controlling rising drug prices, according to a draft report seen by EURACTIV.com.
Pharma industry ‘cannot escape’ drug price talks, say patient groups
Patient groups and the pharmaceutical sector agree that access to medicines needs to be improved - but the way to do it seems to divide them. EURACTIV.com reports from Sofia.
Last-line drug resistance poses ‘alarming’ European health threat
More and more infections in Europe are proving able to evade even the most powerful antibiotics, posing an alarming threat to patient safety in the region, health officials said on Monday (17 November).
Juncker seen making U-turn on medicines policy
Jean-Claude Juncker has ceded to pressure from MEPs and abandoned his plan to return control of medicines and pharmaceutical products to the Industry Commissioner. This responsibility will instead remain in the hands of the Health Commissioner, EURACTIV France reports.Dalli: ‘I’ll be the guardian of consumers’ interests’
Emancipating consumers through information will be the guiding principle of John Dalli's mandate as commissioner for health and consumer policy, if confirmed by the European Parliament.
New EU health chief seizes control of pharma policy
Healthcare lobbyists have scored a major victory in convincing European Commission President José Manuel Barroso to give responsibility for pharmaceuticals to the new health commissioner.
Europe leads global drug discovery: Study
New data shows that Europe is ahead of the United States in pharmaceutical research productivity, contrary to conventional wisdom, argues Professor Donald W. Light in an article published recently in the journal Health Affairs.
Big pharma braced for EU probe closure
The European Commission is today widely expected to confirm earlier allegations that big pharma groups are breaching EU competition rules by blocking the entry of cheaper generics onto the European market.